Total amount: € 0,00
Online ISSN 1827-1707
Gracitelli G. C. 1, 2, Cohen Kaleka C. 3, Bugbee W. D. 1, 4
1 Shiley Center for Orthopedic Research and Education, Scripps Clinic, La Jolla, CA, USA;
2 Department of Orthopedic and Traumatology, Federal University of São Paulo, São Paulo, Brazil;
3 Department of Orthopaedic, Knee Surgery, Division of the Santa Casa School of Medicine and Hospitals of São Paulo, São Paulo, Brazil;
4 Division of Orthopedic Surgery, Scripps Clinic, La Jolla, CA, USA
Osteochondral allograft (OCA) transplantation is an effective surgical treatment option for large cartilage defects in the knee. Tissue availability and safety have had substantial development during the last years with standardization of protocols for harvesting, processing, and storage. Large cartilage lesions, cartilage lesions with bone defects, and failed previous cartilage repair are the main indicators for osteochondral allograft transplantion. Avascular necrosis, posttraumatic arthritis, and bipolar lesions represent challenging diseases and OCA transplantation has been a suitable option for treatment. Ongoing research is needed to improve the chondrocyte viability, reduce costs, reduce time for serological tests, and expand the clinical indication for osteochondral allograft transplantation.